SHIFT Device for Neuropathy

This trial tests a new device called SHIFT, which uses gentle magnetic fields to help cancer patients manage nerve pain from chemotherapy. The trial aims to determine if daily use of this device can reduce pain and ease daily activities. Participants will be divided into two groups: one using the actual device and the other using a placebo device. Ideal candidates are those with chemotherapy-induced nerve pain, who can use a smartphone, and who haven't recently changed their pain treatment.

As an unphased trial, this study provides patients the opportunity to explore innovative pain management solutions before they become widely available.

The trial does not specify if you need to stop taking your current medications. However, if you've had a change in your medical therapy for neuropathy or chronic pain in the last 14 days, you may not be eligible to participate.

Research has shown that the SHIFT device, which uses gentle magnetic fields, is generally safe. Studies on similar methods of magnetic nerve stimulation indicate they can effectively reduce pain without the side effects often seen in more invasive treatments.

Additionally, using electrical stimulation at low levels, like those in SHIFT, is considered safe over the long term. This suggests that using the SHIFT device daily, as planned in the trial, should not pose significant risks.

Unlike the standard treatments for neuropathy, which often involve medications to manage pain and symptoms, the SHIFT device offers a non-invasive approach by directly targeting nerve function. This device is designed to modulate nerve activity, potentially restoring normal nerve function rather than just masking symptoms. Researchers are excited about this treatment because it could offer a safer alternative with fewer side effects compared to traditional drug therapies, and it might provide faster relief for patients with neuropathy.

Research has shown that magnetic fields can help reduce nerve pain. In one study, 71% of patients experienced at least 50% less pain after using magnetic nerve stimulation. Another study found that most participants had significant pain relief and improved quality of life. Additionally, up to 84.6% of patients in certain groups reported feeling less pain. In this trial, participants will receive either the SHIFT device, which uses similar technology, or a sham device. These findings suggest that the SHIFT device might effectively manage nerve pain caused by chemotherapy.¹⁶⁷⁸⁹